Suppr超能文献

亚临床甲状腺功能亢进症自然病程分析

An analysis of the natural course of subclinical hyperthyroidism.

作者信息

Díez Juan J, Iglesias Pedro

机构信息

Department of Endocrinology , Hospital Ramón y Cajal, Madrid, Spain.

出版信息

Am J Med Sci. 2009 Apr;337(4):225-32. doi: 10.1097/maj.0b013e318187e16d.

Abstract

BACKGROUND

Our aim was to evaluate the incidence rate of overt hyperthyroidism in a cohort of patients with subclinical hyperthyroidism and to assess the potential risk factors for the development of overt thyroid hyperfunction.

METHODS

We performed a retrospective analysis in 75 patients (68 women, mean age 62.2 +/- 14.2 years) with subclinical hyperthyroidism and different grades of serum thyrotropin (TSH) suppression. Incidence rate of overt hyperthyroidism and survival time, ie, time without requiring therapy for overt hyperthyroidism, were studied.

RESULTS

Thirty-four patients (45.3%) developed overt hyperthyroidism and 15 (20.0%) reverted to normal TSH values. The incidence rate of overt hyperthyroidism was 9.69 cases per 100 patient-year in the whole population and 4.12, 7.41, and 29.63 cases per 100 patient-year in subjects with initial TSH values of 0.30 to 0.49, 0.10 to 0.29, and <0.10 mU/L, respectively. Kaplan-Meier analysis of survival time curves showed that the development of overt thyroid hyperfunction was significantly related to the presence of symptoms of hyperthyroidism (P < 0.05) and low (<0.10 mU/L) TSH concentrations (P < 0.001). A stepwise multivariate Cox regression analysis showed that both symptoms and low TSH values were significant factors for progression to overt thyrotoxicosis.

CONCLUSIONS

TSH concentration is the most powerful predictor in the outcome of patients with subclinical hyperthyroidism. Our results suggest that patients with values under 0.10 mU/L have the highest probability to develop overt thyroid hyperfunction. In patients with TSH values higher than this value, the risk of progression is notably lower.

摘要

背景

我们的目的是评估亚临床甲状腺功能亢进患者队列中显性甲状腺功能亢进的发病率,并评估发生显性甲状腺功能亢进的潜在危险因素。

方法

我们对75例亚临床甲状腺功能亢进且血清促甲状腺激素(TSH)抑制程度不同的患者(68例女性,平均年龄62.2±14.2岁)进行了回顾性分析。研究了显性甲状腺功能亢进的发病率和生存时间,即无需治疗显性甲状腺功能亢进的时间。

结果

34例患者(45.3%)发生显性甲状腺功能亢进,15例(20.0%)TSH值恢复正常。整个人群中显性甲状腺功能亢进的发病率为每100患者年9.69例,初始TSH值为0.30至0.49、0.10至0.29和<0.10 mU/L的受试者中分别为每100患者年4.12、7.41和29.63例。生存时间曲线的Kaplan-Meier分析表明,显性甲状腺功能亢进的发生与甲状腺功能亢进症状的存在(P<0.05)和低(<0.10 mU/L)TSH浓度(P<0.001)显著相关。逐步多因素Cox回归分析表明,症状和低TSH值都是进展为显性甲状腺毒症的重要因素。

结论

TSH浓度是亚临床甲状腺功能亢进患者预后的最有力预测指标。我们的结果表明,TSH值低于0.10 mU/L的患者发生显性甲状腺功能亢进的可能性最高。TSH值高于此值的患者,进展风险明显较低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验